Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
VMF
0
FDF
0
Europe
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Ca-dtpa
2. Cadtpa
3. Calcium Trisodium Pentetate
4. Cana-dtpa
5. Detapac
6. Diethylenetriamine Pentaacetic Acid
7. Dtpa
8. Indium Dtpa
9. Indium-dtpa
10. Mn-dtpa
11. Pentaacetic Acid, Diethylenetriamine
12. Pentacin
13. Pentacine
14. Pentaind
15. Pentetate Calcium Trisodium
16. Pentetate Zinc Trisodium
17. Pentetate, Calcium Trisodium
18. Pentetates
19. Penthanil
20. Sn-dtpa
21. Zinc Dtpa
22. Zinc-dtpa
1. Diethylenetriaminepentaacetic Acid
2. 67-43-6
3. Dtpa
4. Detapac
5. Detarex
6. Complexon V
7. Titriplex V
8. Perma Kleer
9. Monaquest Cai
10. Hamp-ex Acid
11. Penthanil
12. Dabeersen 503
13. Chel 330 Acid
14. Diethylenetriamine Pentaacetic Acid
15. Pentacarboxymethyldiethylenetriamine
16. Chel Dtpa
17. Pentetate
18. Penthamil
19. Acidum Penteticum
20. H5dtpa
21. (diethylenetrinitrilo)pentaacetic Acid
22. Diethylenetriamine-n,n,n',n'',n''-pentaacetic Acid
23. Detpa
24. 2-[bis[2-[bis(carboxymethyl)amino]ethyl]amino]acetic Acid
25. Glycine, N,n-bis(2-(bis(carboxymethyl)amino)ethyl)-
26. Monaquest
27. 1,1,4,7,7-diethylenetriaminepentaacetic Acid
28. Dtp-a
29. N,n-bis{2-[bis(carboxymethyl)amino]ethyl}glycine
30. Diethylene Triamine Pentaacetic Acid
31. Nsc 7340
32. Glycine, N,n-bis[2-[bis(carboxymethyl)amino]ethyl]-
33. Diethylenetriaminepentacetic Acid
34. Nsc-7340
35. 3,6,9-triazaundecanedioic Acid, 3,6,9-tris(carboxymethyl)-
36. Mfcd00004289
37. N,n-bis[2-[bis(carboxymethyl)amino]ethyl]glycine
38. 7a314hqm0i
39. Chel 330
40. Diethylenetriaminepentaaceticacid
41. Acetic Acid, ((carboxymethylimino)bis(ethylenenitrilo))tetra-
42. Chebi:35739
43. Nsc7340
44. Diethylenetriaminepentaacetate
45. (diethylenetriamine)pentaacetic Acid
46. N,n-bis(2-(bis(carboxymethyl)amino)ethyl)glycine
47. N,n-bis(2-(bis-(carboxymethyl)amino)ethyl)-glycine
48. Acetic Acid, 2,2',2'',2'''-(((carboxymethyl)imino)bis(2,1-ethanediylnitrilo))tetrakis-
49. Diethylenetriaminepentaacetic Acid;dtpa
50. Cas-67-43-6
51. Ncgc00015360-05
52. (((carboxymethyl)imino)bis(ethylenenitrilo))tetraacetic Acid
53. Dissolvine D
54. Dsstox_cid_3434
55. Dsstox_rid_77025
56. Dsstox_gsid_23434
57. Penthamil (van)
58. N,n,n',n'',n''-diethylenetriaminepentaacetic Acid
59. [[(carboxymethyl)imino]bis(ethylenenitrilo)]tetraacetic Acid
60. 2-[bis({2-[bis(carboxymethyl)amino]ethyl})amino]acetic Acid
61. Acido Pentetico
62. Acide Pentetique
63. [[(carboxymethyl)imino]bis(1,2-ethanediylnitrilo)tetraacetic Acid]
64. 2,2',2'',2''',2''''-(ethane-1,2-diylnitrilo)pentaacetic Acid
65. Diethylenetriaminepentaacetic Acid, 99%
66. Acide Pentetique [inn-french]
67. Acido Pentetico [inn-spanish]
68. Acidum Penteticum [inn-latin]
69. Sr-01000075826
70. Einecs 200-652-8
71. Brn 1810219
72. Unii-7a314hqm0i
73. Acetic Acid, [(carboxymethylimino)bis(ethylenenitrilo)]tetra-
74. Pentetic-acid
75. N-carboxymethyliminobis(ethylenenitrilo)tetra(acetic Acid)
76. Acetic Acid, 2,2',2'',2'''-[[(carboxymethyl)imino]bis(2,1-ethanediylnitrilo)]tetrakis-
77. Pentetic Acid [usan:usp:inn:ban]
78. Nanodtpa
79. 2,2'-(carboxymethylimino)bis(ethyliminodiessigsaeure)
80. Pentetic Acid; Dtpa
81. Dtpa (pentetic Acid)
82. Plexene D (salt/mix)
83. Syntron C (salt/mix)
84. Kiresuto P (salt/mix)
85. Tetralon B (salt/mix)
86. Prestwick0_000941
87. Prestwick1_000941
88. Prestwick2_000941
89. Prestwick3_000941
90. Lopac-d-6518
91. Pentetate [vandf]
92. Chel 330 (salt/mix)
93. Chembl780
94. Ec 200-652-8
95. Pentetic Acid (usp/inn)
96. Pentetic Acid [ii]
97. Pentetic Acid [mi]
98. Pentetic Acid [inn]
99. Lopac0_000431
100. Schembl17138
101. Bspbio_000902
102. Pentetic Acid [inci]
103. Pentetic Acid [usan]
104. 4-04-00-02454 (beilstein Handbook Reference)
105. Nanodtpa Component Dtpa
106. Pentetic Acid [vandf]
107. Spbio_003061
108. Pentetic Acid [mart.]
109. Bpbio1_000994
110. Pentetic Acid [usp-rs]
111. Pentetic Acid [who-dd]
112. Dtxsid2023434
113. Hms1570n04
114. Hms2094e03
115. Hms2097n04
116. Hms3261g04
117. Hms3714n04
118. Pharmakon1600-01506082
119. Hy-b1335
120. Tox21_110131
121. Tox21_500431
122. Ac-333
123. Bbl002988
124. Nsc759314
125. S4824
126. Stk373226
127. Zinc19419017
128. Pentetic Acid [usp Monograph]
129. Wln: Qv1n1vq2n1vq2n1vq1vq
130. Akos005446652
131. Tox21_110131_1
132. Ccg-204523
133. Db14007
134. Lp00431
135. Nanodtpa Zn-dtpa Component Dtpa
136. Nsc-759314
137. Sdccgsbi-0050416.p003
138. Nano-dtpa Capsule Component Dtpa
139. Ncgc00015360-01
140. Ncgc00015360-02
141. Ncgc00015360-03
142. Ncgc00015360-04
143. Ncgc00015360-06
144. Ncgc00015360-08
145. Ncgc00015360-09
146. Ncgc00015360-12
147. Ncgc00093852-01
148. Ncgc00093852-02
149. Ncgc00093852-03
150. Ncgc00261116-01
151. Vs-01284
152. Sbi-0050416.p002
153. 1,4,7,7-diethylenetriaminepentaacetic Acid
154. Ab00375916
155. Cs-0013088
156. D0504
157. Eu-0100431
158. Ft-0624901
159. D 6518
160. D05422
161. Diethylenetriaminepentaacetic Acid, P.a., 99%
162. Ab00375916-04
163. Ab00375916_05
164. Diethylenetriamine Pentaacetic Acid [vandf]
165. Diethylenetriamine-n,n',n'',n''-pentaacetic Acid
166. Glycine,n-bis[2-[bis(carboxymethyl)amino]ethyl]-
167. Q416487
168. N,n-bis {2-[bis(carboxymethyl)amino]ethyl}glycine
169. Sr-01000075826-1
170. Sr-01000075826-4
171. Brd-k40621224-001-01-8
172. Diethylenetriaminepentaacetic Acid, >=98% (titration)
173. Diethylenetriaminepentaacetic Acid, >=99% (titration)
174. N, {n-bis[2-[bis(carboxymethyl)amino]ethyl]glycine}
175. Glycine, {n,n-bis[2-[bis(carboxymethyl)amino]ethyl]-}
176. 3,9-triazaundecanedioic Acid, 3,6,9-tris(carboxymethyl)-
177. Diethylenetriamine- N,n,n',n',n''-pentaacetic Acid
178. Dtpa, Diethylenetriamine-n,n,n',n'',n''-pentaacetic Acid
179. (((carboxymethyl)imino)bis(ethylenenitrilo))-tetraacetic Acid
180. {[[(carboxymethyl)imino]bis(ethylenenitrilo)]tetraacetic} Acid
181. Acetic Acid, {[(carboxymethylimino)bis(ethylenenitrilo)]tetra-}
182. Diethylenetriaminepentaacetic Acid, For Complexometry, >=99.0%
183. Pentetic Acid, United States Pharmacopeia (usp) Reference Standard
184. Acetic Acid,2',2'',2'''-[[(carboxymethyl)imino]bis(2,1-ethanediylnitrilo)]tetrakis-
185. 1004765-76-7
186. 2,2',2'',2'''-(2,2'-(carboxymethylazanediyl)bis(ethane-2,1-diyl)bis(azanetriyl))tetraacetic Acid
| Molecular Weight | 393.35 g/mol |
|---|---|
| Molecular Formula | C14H23N3O10 |
| XLogP3 | -8.5 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 13 |
| Rotatable Bond Count | 16 |
| Exact Mass | 393.13834394 g/mol |
| Monoisotopic Mass | 393.13834394 g/mol |
| Topological Polar Surface Area | 196 Ų |
| Heavy Atom Count | 27 |
| Formal Charge | 0 |
| Complexity | 481 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | An-dtpa |
| PubMed Health | Technetium Tc 99m Pentetate (Injection) |
| Drug Classes | Diagnostic Agent, Radiopharmaceutical Imaging |
| Drug Label | Each kit consists of reaction vials which contain the sterile, non-pyrogenic, non-radioactive ingredients necessary to produce Technetium Tc 99m Pentetate Injection for diagnostic use by intravenous injection. Each 10 mL reaction vial contains 20 mg... |
| Active Ingredient | Technetium tc-99m pentetate kit |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | n/a |
| Market Status | Prescription |
| Company | Jubilant Draximage |
| 2 of 4 | |
|---|---|
| Drug Name | Dtpa |
| Active Ingredient | Technetium tc-99m pentetate kit |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | n/a |
| Market Status | Prescription |
| Company | Draximage |
| 3 of 4 | |
|---|---|
| Drug Name | An-dtpa |
| PubMed Health | Technetium Tc 99m Pentetate (Injection) |
| Drug Classes | Diagnostic Agent, Radiopharmaceutical Imaging |
| Drug Label | Each kit consists of reaction vials which contain the sterile, non-pyrogenic, non-radioactive ingredients necessary to produce Technetium Tc 99m Pentetate Injection for diagnostic use by intravenous injection. Each 10 mL reaction vial contains 20 mg... |
| Active Ingredient | Technetium tc-99m pentetate kit |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | n/a |
| Market Status | Prescription |
| Company | Jubilant Draximage |
| 4 of 4 | |
|---|---|
| Drug Name | Dtpa |
| Active Ingredient | Technetium tc-99m pentetate kit |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | n/a |
| Market Status | Prescription |
| Company | Draximage |
DTPA is widely used in industry and medicine. As a medical agent, it is approved for its use in medical imaging and for the decorporation of internally deposited radionuclides. It is FDA approved for the treatment of individuals with known or suspected internal contamination with plutonium, americium or curium to increase the rates of elimination. Due to the pharmacokinetic elimination by the kidneys, pentetic acid conjugated with technetium Tc-99m is being used clinically to estimate physiological parameters such as glomerular filtration rat and effective renal plasma flow.
FDA Label
There are reports in vivo of low stability of complexes of DPTA with uranium and neptunium which is being reported to cause deposition of the radionuclides into the tissues. In the case of plutonium, some preclinical studies have shown a very high urine elimination efficacy 1 hour after initial contamination. This efficacy is conserved for approximately 24 hours while the radiocontaminant is circulating. When the radionuclide is inhaled, it has been reported a DPTA-induced reduction of even 98% of the lung deposits. It is important to consider that pentetic acid can bind directly to other trace metals in the body which can cause deficiencies.
Chelating Agents
Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. (See all compounds classified as Chelating Agents.)
Iron Chelating Agents
Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of hemoglobin is an example of a metal chelate found in biological systems. (See all compounds classified as Iron Chelating Agents.)
Antidotes
Agents counteracting or neutralizing the action of POISONS. (See all compounds classified as Antidotes.)
Absorption
DTPA and its trisodium salts present a very poor bioavailability after oral administration. Therefore, the normal administration of DTPA is done by slow intravenous infusion or inhalation with a nebulizer. When inhaled, the absorption is of about 20% of the administered dose.
Route of Elimination
DTPA metal complexes are quickly excreted in the urine.It is predominantly excreted by the kidney and it is not excreted by non-renal routes to any significant extent.
Volume of Distribution
The volume of distribution of DPTA is 17 L.
Clearance
Pentetic acid presents a very rapid blood clearance which explains for the short half-life. The reported clearance rate in patients with normal renal function is 80-120ml/min.
Pentetic acid and its derivatives present a very minimal metabolism in the body.
In preclinical studies, DTPA has been shown to present a very short half-life of 18.5-31.8 min after intravenous administration.
The calcium and zinc trisodium salts of DTPA achieve the therapeutical potential by exchanging calcium and zinc cations with transuranic radionuclides to form higher affinity complexes and then promote their elimination by glomerular filtration into the urine. DTPA as an acid acts in a very similar way by sequestering ions with its eight coordinate bond forming sites.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
BioLexa (gentamicin) is a patented, proprietary antimicrobial topical formulation being developed for treatment of diseases mediated by Staphylococcal biofilms. Bacterial biofilms are specialized communities consisting of bacteria adhered to a surface and to other bacteria.
Lead Product(s): Gentamicin Sulfate,Pentetic Acid
Therapeutic Area: Dermatology Brand Name: BioLexa
Study Phase: Phase IProduct Type: Small molecule
Sponsor: H.C. Wainwright & Co.
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 03, 2023
Lead Product(s) : Gentamicin Sulfate,Pentetic Acid
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : H.C. Wainwright & Co.
Deal Size : $10.0 million
Deal Type : Private Placement
Details : BioLexa (gentamicin) is a patented, proprietary antimicrobial topical formulation being developed for treatment of diseases mediated by Staphylococcal biofilms. Bacterial biofilms are specialized communities consisting of bacteria adhered to a surface an...
Brand Name : BioLexa
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 03, 2023
Details:
BioLexa (gentamicin) is a patented, proprietary antimicrobial topical formulation being developed for treatment of diseases mediated by Staphylococcal biofilms. The BioLexa formulation is optimized to prevent Staphylococcal biofilm formation.
Lead Product(s): Gentamicin Sulfate,Pentetic Acid
Therapeutic Area: Dermatology Brand Name: BioLexa
Study Phase: Phase IProduct Type: Small molecule
Sponsor: H.C. Wainwright & Co.
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 29, 2022
Lead Product(s) : Gentamicin Sulfate,Pentetic Acid
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : H.C. Wainwright & Co.
Deal Size : $10.0 million
Deal Type : Private Placement
Hoth Therapeutics Announces $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Details : BioLexa (gentamicin) is a patented, proprietary antimicrobial topical formulation being developed for treatment of diseases mediated by Staphylococcal biofilms. The BioLexa formulation is optimized to prevent Staphylococcal biofilm formation.
Brand Name : BioLexa
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 29, 2022
Details:
Receiving clearance for Cohort 2 is the next critical milestone in the Phase 1b clinical trial in Australia. Hoth's atopic dermatitis solution, BioLexa, represents a significant global opportunity and looks forward to advancing the treatment through the clinic.
Lead Product(s): Gentamicin Sulfate,Pentetic Acid
Therapeutic Area: Dermatology Brand Name: BioLexa
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2021
Lead Product(s) : Gentamicin Sulfate,Pentetic Acid
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Receiving clearance for Cohort 2 is the next critical milestone in the Phase 1b clinical trial in Australia. Hoth's atopic dermatitis solution, BioLexa, represents a significant global opportunity and looks forward to advancing the treatment through the ...
Brand Name : BioLexa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 12, 2021
Details:
BioLexa is patented, proprietary antimicrobial topical formulation against diseases mediated by Staphylococcal biofilms. BioLexa formulation is optimized to prevent Staphylococcal biofilm formation, keeping bacteria in more susceptible state to antimicrobial therapy.
Lead Product(s): Gentamicin Sulfate,Pentetic Acid
Therapeutic Area: Dermatology Brand Name: BioLexa
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2021
Lead Product(s) : Gentamicin Sulfate,Pentetic Acid
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BioLexa is patented, proprietary antimicrobial topical formulation against diseases mediated by Staphylococcal biofilms. BioLexa formulation is optimized to prevent Staphylococcal biofilm formation, keeping bacteria in more susceptible state to antimicro...
Brand Name : BioLexa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 21, 2021
Details:
The first in human clinical trial is randomized, double-blind, vehicle controlled study to determine the safety, tolerability, PK and efficacy of twice daily application of topical BioLexa™ lotion, in adult and adolescent patients with mild to moderate AD.
Lead Product(s): Gentamicin Sulfate,Pentetic Acid
Therapeutic Area: Dermatology Brand Name: BioLexa
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Novotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2021
Lead Product(s) : Gentamicin Sulfate,Pentetic Acid
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Novotech
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The first in human clinical trial is randomized, double-blind, vehicle controlled study to determine the safety, tolerability, PK and efficacy of twice daily application of topical BioLexa™ lotion, in adult and adolescent patients with mild to moderate...
Brand Name : BioLexa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 22, 2021
Details:
The Company currently intends to use the net proceeds from the private placement for further development of Hoth's product candidates including lead drug BioLexa and for working capital and general corporate purposes.
Lead Product(s): Gentamicin Sulfate,Pentetic Acid
Therapeutic Area: Dermatology Brand Name: BioLexa
Study Phase: Phase IProduct Type: Small molecule
Sponsor: H.C. Wainwright & Co.
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 08, 2021
Lead Product(s) : Gentamicin Sulfate,Pentetic Acid
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : H.C. Wainwright & Co.
Deal Size : $15.0 million
Deal Type : Private Placement
Hoth Therapeutics Announces $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Details : The Company currently intends to use the net proceeds from the private placement for further development of Hoth's product candidates including lead drug BioLexa and for working capital and general corporate purposes.
Brand Name : BioLexa
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 08, 2021
Details:
Hoth Therapeutics has completed recruitment of Cohort 1 for its upcoming first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema.
Lead Product(s): Gentamicin Sulfate,Pentetic Acid
Therapeutic Area: Dermatology Brand Name: BioLexa
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2021
Lead Product(s) : Gentamicin Sulfate,Pentetic Acid
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Hoth Therapeutics has completed recruitment of Cohort 1 for its upcoming first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema.
Brand Name : BioLexa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 01, 2021
Details:
Following the successful completion of the Phase 1b trial, the Company intends to conduct a Phase 2 trial with adult and adolescent patients to continue clinical investigation of the efficacy of BioLexa Lotion for treatment of mild to moderate atopic dermatitis.
Lead Product(s): Gentamicin Sulfate,Pentetic Acid
Therapeutic Area: Dermatology Brand Name: BioLexa
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2020
Lead Product(s) : Gentamicin Sulfate,Pentetic Acid
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Following the successful completion of the Phase 1b trial, the Company intends to conduct a Phase 2 trial with adult and adolescent patients to continue clinical investigation of the efficacy of BioLexa Lotion for treatment of mild to moderate atopic der...
Brand Name : BioLexa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Direct Compression
Fillers, Diluents & Binders
Chewable & Orodispersible Aids
Taste Masking
Parenteral
Co-Processed Excipients
Digital Content
DATA COMPILATION #PharmaFlow
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
